March 19th 2021
By Tony Hagen
Following lackluster experience with biosimilar marketing in the United States, Merck moves forward with spinoff plan.
March 17th 2021
Pfizer said it has made a business decision to cease production of biosimilars at a $350 million plant it built recently in Hangzhou, China.
March 15th 2021
Alvotech closes on $35 million in funding, and Samsung Bioepis gets closer to marketing an adalimumab biosimilar. Alvotech's planned high-tech expansion is pictured.
March 13th 2021
The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
March 11th 2021
By Deana Ferreri, PhD
Unsustainably low prices for generics are preventing some manufacturers from producing them, while biosimilars are blocked by policies that favor originator drugs, the Association for Accessible Medicines (AAM) argues.
March 9th 2021
Alteogen is among a number of contenders vying to bring aflibercept biosimilars to market. Key patents on the originator begin to expire in 2023.
March 2nd 2021
Biocon and Viatris edge closer to EU marketing authorization for a bevacizumab biosimilar, among other biosimilar business developments.
February 27th 2021
By Sarfaraz K. Niazi, PhD
Biosimilars have come a long way, and their path has mirrored that of generics—fraught with obstacles. Still, a stronger embrace is needed from physicians and payers.
February 25th 2021
Sales of the pegfilgrastim oncology support biosimilar Udenyca fell off in late 2020, but Coherus doesn't see orginator company Amgen's advantage lasting much longer.
February 22nd 2021
Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.
